Zuventus Healthcare Launches Floresp-OX: A Combination Nasal Spray for Allergic Rhinitis

 

Continuing its focus on patient-centric innovation, Zuventus Healthcare has introduced Floresp-OX, a novel combination nasal spray designed to manage the dual challenges of nasal inflammation and congestion associated with allergic rhinitis.

A Dual-Action Approach

Allergic rhinitis is one of the most common respiratory conditions, affecting millions worldwide with symptoms such as sneezing, congestion, and nasal blockage. While treatments exist, many patients struggle to balance long-term relief with safety in daily use. Floresp-OX addresses this gap by combining:

• Fluticasone Furoate (intranasal steroid): Reduces inflammation and prevents long-term nasal swelling.
• Oxymetazoline (nasal decongestant): Provides rapid relief from congestion by shrinking swollen nasal passages.

This combination offers patients the convenience of a single nasal spray while ensuring both fast onset of action and sustained control of symptoms.

Reducing Risks with Smarter Therapy

Standalone use of decongestants like oxymetazoline is often associated with rebound congestion when used for prolonged periods. By pairing it with Fluticasone Furoate, Floresp-OX minimizes this risk and helps prevent tachyphylaxis (diminished drug response over time). This makes the therapy a more reliable option for patients needing longer-term management.

Indications and Dosage

Floresp-OX is recommended for patients aged 12 years and above. The advised dosage is two spray actuations (27.5 mcg of Fluticasone and 50 mcg of Oxymetazoline per actuation) in each nostril once daily. The formulation offers both convenience and clinical precision, ensuring patients receive an effective and controlled therapy.

Industry Perspective

Experts note that the launch of Floresp-OX underscores Zuventus’ commitment to strengthening its respiratory care portfolio. By offering combination therapy in a simple delivery system, the company aims to improve adherence and outcomes for individuals living with allergic rhinitis.

As the burden of respiratory conditions grows globally, innovations like Floresp-OX reflect the evolving approach of pharmaceutical companies that combine efficacy, safety, and convenience in patient care.